January 15, 2020 / 6:10 AM / 12 days ago

BRIEF-OBSEVA: Phase 2 Results Of Obe022 Expected In H2 2020

Jan 15 (Reuters) - OBSEVA SA:

* PHASE 3 LINZAGOLIX TRIALS EXPECTED TO GENERATE ADDITIONAL DATA IN UTERINE FIBROIDS IN Q2:20 WITH FIRST LINZAGOLIX REGULATORY FILING PLANNED FOR LATE 2020

* ENROLLMENT OF LINZAGOLIX US AND EU PHASE 3 TRIALS IN ENDOMETRIOSIS ON TRACK

* PHASE 2 RESULTS OF OBE022 EXPECTED IN 2H:20 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below